Vicept Therapeutics

About Vicept Therapeutics

Vicept Therapeutics, Inc. operated as a specialty pharmaceutical company with a sharp focus on dermatology, specifically developing treatments for skin redness, or erythema, associated with conditions like rosacea. The company was founded in 2009 by Dr. Neal Walker, a board-certified dermatologist who served as its President and CEO. Dr. Walker's background as a clinician provided a direct line of sight into unmet needs within the dermatology market. He previously co-founded Octagon Research Solutions, which was acquired by Accenture. Following the sale of Vicept, Dr. Walker and his management team went on to form Aclaris Therapeutics, continuing their focus on dermatological treatments.

The company's business model was centered on identifying and developing novel therapeutics for prevalent skin disorders that lacked effective treatments. Its primary market was the substantial population suffering from rosacea, a chronic condition affecting over 15 million people in the U.S. and more than 45 million globally. Vicept's strategy involved advancing its lead product candidate through clinical trials to demonstrate safety and efficacy, with the ultimate goal of commercialization or a strategic acquisition. The company's operations were financed through venture capital, securing a $16 million Series A round from investors including Vivo Ventures, Fidelity Biosciences, and Sofinnova Ventures.

Vicept's lead product was V-101, a topical cream developed for the treatment of erythematotelangiectatic rosacea (ETR), the most common subtype characterized by facial redness and flushing. The key benefit of V-101 was its targeted action on the underlying cause of redness. The active molecule, which had been used for decades in ocular and nasal applications, binds to alpha-adrenergic receptors on cutaneous blood vessels, causing them to constrict, thereby reducing facial redness. The company successfully completed two Phase II clinical trials which demonstrated that V-101 was well-tolerated and showed a statistically significant improvement in reducing facial erythema compared to a placebo. This success was a major milestone, positioning V-101 as a potential first-in-class therapy. The company's pipeline also included early-stage candidates for treating bruising (actinic purpura) and peri-procedural bruising.

Demonstrating a rapid and successful trajectory for a drug development firm, Vicept Therapeutics was acquired by Allergan in July 2011, merely two years after its inception. The deal involved a $75 million upfront cash payment, with potential future payments up to an aggregate of $200 million based on development, regulatory, and sales milestones. The acquisition provided a strategic exit for its investors and placed V-101 within the pipeline of a major pharmaceutical company with the resources to complete late-stage development and commercialization.